Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?

Detalles Bibliográficos
Autores principales: Negri, Francesca, Porta, Camillo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477309/
https://www.ncbi.nlm.nih.gov/pubmed/34667489
http://dx.doi.org/10.4081/oncol.2021.564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477309/
https://www.ncbi.nlm.nih.gov/pubmed/34667489
http://dx.doi.org/10.4081/oncol.2021.564

Ejemplares similares